Rafael (RFL) AVENGER 500 Phase 3 clinical trial evaluating CPI-613 in combination with modified FOLFIRINOX (mFFX) as a first-line therapy in patients misses primary endpoint

Go back to Rafael (RFL) AVENGER 500 Phase 3 clinical trial evaluating CPI-613 in combination with modified FOLFIRINOX (mFFX) as a first-line therapy in patients misses primary endpoint
RYDEX 2X S&P SELECT SECTOR FINANCIAL ETF (NYSE: RFL) Delayed: 4.35 --0 (-0%)
Previous Close $4.35    52 Week High $17.54 
Open $4.35    52 Week Low $0.15 
Day High $4.35    P/E N/A 
Day Low $4.35    EPS $0.00 
Volume 110